139 related articles for article (PubMed ID: 34895218)
1. Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trial.
Maspero J; Agache IO; Kamei T; Yoshida M; Boone B; Felser JM; Kawakami F; Knorr B; Lawrence D; Lehmann T; Wang W; Pedinoff AJ
Respir Res; 2021 Dec; 22(1):311. PubMed ID: 34895218
[TBL] [Abstract][Full Text] [Related]
2. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
Gonem S; Berair R; Singapuri A; Hartley R; Laurencin MFM; Bacher G; Holzhauer B; Bourne M; Mistry V; Pavord ID; Mansur AH; Wardlaw AJ; Siddiqui SH; Kay RA; Brightling CE
Lancet Respir Med; 2016 Sep; 4(9):699-707. PubMed ID: 27503237
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials.
Brightling CE; Gaga M; Inoue H; Li J; Maspero J; Wenzel S; Maitra S; Lawrence D; Brockhaus F; Lehmann T; Brindicci C; Knorr B; Bleecker ER
Lancet Respir Med; 2021 Jan; 9(1):43-56. PubMed ID: 32979986
[TBL] [Abstract][Full Text] [Related]
4. Fevipiprant, an oral prostaglandin DP
Bateman ED; Guerreros AG; Brockhaus F; Holzhauer B; Pethe A; Kay RA; Townley RG
Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28838980
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2).
Castro M; Kerwin E; Miller D; Pedinoff A; Sher L; Cardenas P; Knorr B; Lawrence D; Ossa D; Wang W; Maspero JF
EClinicalMedicine; 2021 May; 35():100847. PubMed ID: 33997741
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
[TBL] [Abstract][Full Text] [Related]
8. The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.
Erpenbeck VJ; Popov TA; Miller D; Weinstein SF; Spector S; Magnusson B; Osuntokun W; Goldsmith P; Weiss M; Beier J
Pulm Pharmacol Ther; 2016 Aug; 39():54-63. PubMed ID: 27354118
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Prostaglandin D2 Receptor 2 Antagonism with Fevipiprant for Patients with Asthma: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
Yang D; Guo X; Liu T; Li Y; Du Z; Liu C
Curr Allergy Asthma Rep; 2021 Aug; 21(7):39. PubMed ID: 34387775
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
12. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
13. Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER).
Gevaert P; Bachert C; Maspero JF; Cuevas M; Steele D; Acharya S; Altman P
J Allergy Clin Immunol; 2022 May; 149(5):1675-1682.e3. PubMed ID: 35094848
[TBL] [Abstract][Full Text] [Related]
14. The pharmacology of the prostaglandin D
Brightling C; Kulkarni S; Lambrecht BN; Sandham D; Weiss M; Altman P
Pulm Pharmacol Ther; 2021 Jun; 68():102030. PubMed ID: 33826946
[TBL] [Abstract][Full Text] [Related]
15. A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids.
Kerwin E; Pascoe S; Bailes Z; Nathan R; Bernstein D; Dahl R; von Maltzahn R; Robbins K; Fowler A; Lee L
Respir Res; 2020 Jun; 21(1):148. PubMed ID: 32532275
[TBL] [Abstract][Full Text] [Related]
16. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
17. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
Virchow JC; Kuna P; Paggiaro P; Papi A; Singh D; Corre S; Zuccaro F; Vele A; Kots M; Georges G; Petruzzelli S; Canonica GW
Lancet; 2019 Nov; 394(10210):1737-1749. PubMed ID: 31582314
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial.
Brown MN; Fuhr R; Beier J; Su HL; Chen Y; Forsman H; Hamrén UW; Jackson H; Aggarwal A
Respir Res; 2019 Feb; 20(1):37. PubMed ID: 30777086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
